FDA
approval
· 2023-02-27
FDA Approved: CABENUVA — Supplemental Application (ViiV Healthcare Company)
Summary
The FDA approved a supplemental application for CABENUVA, the long-acting HIV-1 treatment regimen of cabotegravir and rilpivirine, filed by ViiV Healthcare Comp…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for CABENUVA (CABOTEGRAVIR AND RILPIVIRINE)